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Summary
Purpose. To assess the acceptability of new non-invasive breast cancer diagnostic tests intended to triage women
in need of biopsy.
Methods. Women who had abnormal screening tests and had been recommended to have a biopsy were invited
to receive digital mammography, magnetic resonance imaging (MRI), and nuclear medicine evaluation (Tc-99m-
sestamibi scanning) before biopsy. Participants completed a questionnaire about satisfaction and acceptability of
the procedures. Satisfaction measured women’s overall and test-specific satisfaction. Acceptability was measured
by self-reported discomfort, embarrassment and women’s preference in terms of willingness to pay to avoid a
biopsy.
Results. Women were satisfied with all of the potential diagnostic triage procedures. Most found the tests more
comfortable than a routine mammogram (47, 50, and 66% undergoing MRI, digital mammography, and sestamibi
scanning, respectively). Women who provided a response to willingness to pay questions (N = 43) were willing
to pay an average of $611 to have a test instead of a biopsy, if the test was as accurate as biopsy. The willingness to
pay significantly decreased to $308 if the test only had 95% accuracy. Those who had prior benign breast disease
were less willing to pay for a test with 95% accuracy than those without this history.
Conclusion. Instead of immediate biopsy after an abnormal screening, these results suggest that women would
find non-invasive triage tests acceptable, or preferable to biopsy if they were equally accurate or nearly equally
accurate as a biopsy. New technologies to diagnose breast cancer should focus on decreasing discomfort as well as
increasing test accuracy.
Introduction
There are more than 600,000 breast biopsies per-
formed annually in the US [1]; as many as 80% of
these yield benign results [2, 3]. While biopsies are
the definitive tests for diagnosing cancer, they are inva-
sive, and can be uncomfortable and anxiety provoking.
Thus, alternative, non-invasive diagnostic pathways
could have large potential economic and quality of life
impact [4, 5].
However, when making decision on using non-
invasive diagnostic tests, women must balance the
concerns of discomfort and anxiety from biopsies
against the possibility of reduced accuracy of the non-
invasive tests. A false positive result would result in a
biopsy anyway, so the diagnostic pathway would in-
clude one more test than if the woman had a biopsy
immediately following the abnormal mammogram or
breast examination. Perhaps of more concern to wom-
en would be a false negative on the new test, missing a
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breast cancer resulting in a delay in diagnosis. Thus, as
novel diagnostic tests are introduced into practice, wo-
men must balance the benefits of potentially avoiding
a biopsy with the risks of a potentially less accurate
diagnostic test.
Although new non-invasive technologies are being
developed to increase the accuracy of detecting breast
cancer [6–9], there are no studies that we are aware
of that have examined the acceptability of these tech-
nologies from the perspective of patients who receive
them. The purpose of this project is two-fold. First,
among a cohort of women who had an abnormal breast
finding and were recommended to have a biopsy, we
assess the patient’s perspective on the acceptability
of new diagnostic radiology technologies. Our second
objective is to understand how test accuracy is related
to women’s preferences for avoiding a biopsy in favor
of a non-invasive diagnostic test.
Methods
Study sample and procedures
We prospectively enrolled a cohort of white and
African-American women from several DC-
metropolitan area clinics, hospitals, and HMOs, who
had abnormal breast physical examination, mam-
mography, and/or clinical ultrasound examination
(usually done on the identified palpable abnormal-
ity and performed without Doppler imaging) re-
sults and had been recommended to have a breast
biopsy between June 1998 and October 2000. After
providing informed consent, participants received a
series of breast cancer diagnostic tests, including
digital mammography, magnetic resonance imaging
(Gd-DTPA enhanced MRI), and nuclear medicine
evaluation (Tc-99m-sestamibi scanning). A short self-
administered questionnaire about satisfaction and ac-
ceptability of the tests was given to women after
completion of all tests. Both the diagnostic tests
and the survey were done on the same day visit,
which was scheduled prior to receiving their breast
biopsy. To minimize test selection bias, women
were asked to receive all the diagnostic tests and
no information on the sensitivity and specificity of
individual tests were given at the consenting pro-
cess. Failure to receive certain tests was largely
due to unavailability of those tests on the day
of visit (e.g., equipment breakage and scheduling
conflicts).
Measures
Patient characteristics included age, monthly house-
hold income, previous breast biopsy, history of benign
breast disease, history of breast cancer, family history
of breast cancer, and women’s perceived risk of getting
breast cancer in the future.
Satisfaction with participating in this study and
with the overall experience of receiving each indi-
vidual diagnostic test was measured using a modi-
fication of the Medical Outcomes Study Visit Rating
Questionnaire [10]. The six satisfaction questions
measured satisfaction with the receipt of the tests over-
all, the technical skill of the staff, the personal manner
of the staff, the convenience of getting the tests, the
length of time spent waiting for the test, and the
explanation of what was done for the participants. Re-
sponses to each question were rated on a five-item
Likert scale.
Discomfort associated with having a routine mam-
mogram was measured using a five-item Likert scale
(extremely, very, somewhat, mildly, and not uncom-
fortable at all). To provide a relative standard, we
asked the participants to rate discomfort of other tests
compared to having a routine mammogram (a lot
less, a little less, no different, a little more, a lot
more). Embarrassment was measured using a four-
item Likert scale (extremely, somewhat, mildly, and
not embarrassing at all) for each test.
The willingness to pay technique was used to
assess women’s preferences for having one of the
non-invasive diagnostic tests compared to a surgical
biopsy. We used the willingness to pay technique as
a process utility, or a quantitative measure of pref-
erence that may be applied to the process of care
[11–15]. The willingness to pay questions ask re-
spondents how much money they think women like
themselves would be willing to pay out-of-pocket for
an alternative non-invasive diagnostic test instead of a
biopsy. We worded these questions in the third per-
son to reduce the potential for anxiety about breast
cancer in women undergoing evaluation for a suspi-
cious breast lesion. Two willingness to pay scenarios
were used to evaluate the impact of diagnostic accu-
racy on preferences. The first asks about willingness
to pay to have a test instead of a biopsy, if the test
were as accurate as a biopsy at diagnosing cancer. The
second asks about willingness to pay if the test were
nearly (95%) as accurate as a biopsy. The reason for
using 95% accuracy rate was to assess how preference
changes for tests that are slightly less accurate than the
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‘gold standard’, in this case, breast biopsy. We asked
participants to imagine whichever new test they would
most prefer having, to avoid the respondent burden of
asking about each test separately. Thus, the assessment
provides the maximum the respondent would be will-
ing to pay for any of the tests. Since the willingness to
pay technique is sensitive to economic status, willing-
ness to pay was further defined as the amount a woman
thinks women like her would be willing to pay as a
proportion household income.
Data analysis
Analyses were performed using the SAS System ver-
sion 8. Patient satisfaction, discomfort, and embar-
rassment scales were analyzed by frequencies and the
non-parametric Kruskal–Wallis tests for difference in
distribution. The differences in willingness to pay by
patient characteristics were presented by the average
amount of money women would be willing to pay in
individual scenarios and the ratio of the result for the
two scenarios using t tests and ANOVA tests. Because
of the small sample size and non-normal distribution
of the ratio between willingness to pay and income, the
non-parametric Kruskal–Wallis test was used to test
the difference in willingness to pay by patient char-
acteristics. Finally, the difference in the ratio between
the two willingness to pay values (95 v.s. 100% accu-




A total of 106 patients were recruited for this study,
82 (77%) of which completed the survey. Those who
completed the survey were similar with respect to
demographics and cancer history as those who did not
complete the survey. The mean age of this sample was
51.6 (range= 25–78) (Table 1). Eighty percent were
white, and 14% were African Americans. About 23%
had a monthly household income of up to $3000, and
13 and 64% had an income level of $3000–4999 and
$5000 and above, respectively. Prior to entry into this
study, about 46% (N = 37) had a history of a prior
breast biopsy; 10 of these had benign breast disease,
two were diagnosed with ductal carcinoma in situ
(DCIS), one had lobular carcinoma in situ (LCIS),
nine had other types of breast malignancy, and 15
did not report having any kind of breast disease. Of
Table 1. Participant characteristics (N = 82)
Patient characteristics Distribution
Age
40 and younger 13.6%
41–50 32.1%
51–60 37.0%
61 and older 17.3%








Less than $1000 3.1%
$1000 to $1999 6.3%
$2000 to $2999 14.1%
$3000 to $3999 1.6%
$4000 to $4999 10.9%
$5000 or more 64.1%
Previous breast biopsy 46.3%
History of benign breast disease 21.3%
History of DCIS 2.6%
History of LCIS 1.3%
History of breast malignancy
other than LCIS and DCIS 11.4%
Family history of breast cancer 45%
Family history of ovarian cancer 2.5%
the 17 (21.3%) women with a benign breast disease,
seven did not receive a breast biopsy prior to the study.
Thirty-six participants had a family history of breast
cancer, and two had a family history of ovarian cancer.
Satisfaction with care
In general, participants were very satisfied with the
process of receiving the different diagnostic tests
(Table 2). About 96% of patients gave an excellent or
very good rating of the overall process of participating
in the study.
Acceptability – degree of discomfort
About 20% of the participants reported that a routine
mammogram made them very or extremely uncom-
fortable, and another 20% reported mammography as
not uncomfortable at all (Figure 1). Among those re-
ceiving the tests, 47% of those receiving MRI, 50%
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Table 2. Patient satisfaction with the diagnostic process
Overall Technical skills Personal manner Convenience Time spent in waiting Explanation
N 79 66 80 81 79 81
Excellent (%) 73 83 89 43 62 80
Very good (%) 23 15 9 40 28 16
Good (%) 1 1 1 14 5 4
Fair (%) 3 1 1 2 5 0
Poor (%) 0 0 0 1 0 0
Figure 1. Women’s report of discomfort experienced in routine mammography.
of those receiving digital mammography, and 66%
of those receiving sestamibi imaging found the pro-
cedure more comfortable than a routine mammogram
(Table 3). Compared to routine mammography, the
sestamibi nuclear medicine test was perceived as the
most comfortable test.
Acceptability – degree of embarrassment
Most of the participants did not feel embarrassed when
receiving any of the diagnostic tests (Table 4).
Preference – willingness to pay
Under conditions of equal accuracy to a biopsy,
women were willing to pay an average of $611 to
have a non-invasive test instead of a biopsy (range
$0–10,000), with 7% of women not willing to pay any
money out of pocket (Table 5). The willingness to pay
significantly decreased to an average of $308 in the
case of 95% accuracy (range $0–3000), with 33% of
women not willing to pay any money (p < 0.0001).
This decrease of willingness to pay was consistent
across patient characteristics.
Regarding the difference in willingness to pay by
patient characteristics, women who had a history of
benign breast disease tended to be willing to pay less
to avoid a biopsy than women without history of breast
disease. There was no difference in willingness to
pay by age, perceived vulnerability of breast cancer,
household income, history of biopsy, history of breast
cancer, and family history of breast cancer (Table 5).
However, interesting non-significant trends were ob-
served in several categories: Women ages 60 and older
were less willing to pay out of their own pockets for
diagnostic tests (e.g., willing to pay $220 compared
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Table 3. Discomfort experienced from diagnostic tests compared to a routine mammogram
Discomfort compared to routine MRI [55 (67%)] Digital mammogram Nuclear medicine
mammogram (score) [14 (17%)] [71 (87%)]
A lot less (2) 27% 14% 45%
A little less (1) 20% 36% 21%
No different (0) 15% 50% 13%
A little more (−1) 16% – 18%
A lot more (−2) 22% – 3%
Mean score 0.15 0.64 0.87
Table 4. Embarrassment experienced from diagnostic tests
Embarrassment level Routine mammogram MRI Digital mammogram Nuclear medicine
N 80 53 14 72
Not embarrassing at all (%) 76 87 93 83
Mildly embarrassing (%) 11 11 7 11
Somewhat embarrassing (%) 11 0 0 4
Extremely embarrassing (%) 1 2 0 1
Note: Kruskal–Wallis tests showed no significant difference among routine mammogram, MRI, digital mammo-
gram, and nuclear medicine.
to $962 among women aged 50–59). Those who had
previous biopsy with benign results were willing to
spend more for other non-invasive tests (willing to
pay $589); whereas those with a history of abnor-
mal biopsy results would pay less for diagnostic tests
other than biopsy (willing to pay $116). Women with
breast cancer or family history of breast cancer were
less willing to pay for other diagnostic tests (will-
ing to pay $200 and $236, compared to $315 and
$377 among those without history or family history
of breast cancer).
Discussion
This study demonstrated that new non-invasive breast
cancer diagnostic tests (digital mammography, MRI,
and sestamibi nuclear medicine) are generally accept-
able (in terms of level of discomfort and embarrass-
ment) to women who have abnormal breast findings
and for whom a breast biopsy is recommended.
Women generally consider these new diagnostic tests
more comfortable than a routine mammogram. The
degree of embarrassment from taking these tests
are similar to that seen with routine mammograms.
Prior research shows that discomfort associated with
mammography is a barrier to regular breast cancer
screening [16, 17]. Decreasing women’s physical
discomfort while receiving breast cancer diagnostic
tests may likewise be an important objective to ensure
compliance with timely follow-up.
The acceptability of new diagnostic test is influ-
enced by test accuracy. In our study, the importance
of test accuracy was assessed by women’s willing-
ness to pay for the test out of their own pocket. A
decrease of 5% accuracy, from 100 to 95%, of the pre-
ferred test resulted in a 40% decrease of willingness
to pay, and the sizable decrease was consistent across
different age, biopsy history, breast disease, family
history of breast cancer, and risk perception groups.
These results suggest that the accuracy of diagnostic
tests may be more important than the level of dis-
comfort and embarrassment associated with a test.
Because test accuracy will have impact on long-term
health outcomes, women may prefer a more uncom-
fortable but more accurate test to avoid getting false
diagnosis.
Moreover, the willingness to pay measure showed
that women with previous benign breast disease ten-
ded to be more willing to pay for new diagnostic tests
to avoid unnecessary biopsies than those with no be-
nign breast disease. It is possible that a benign disease
history is acting as a proxy for experience with breast
biopsies, alternatively, women with prior benign
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Table 5. Willingness to pay according to accuracy of diagnostic tests, by patient characteristics
100% accuracy (A) Mean (SD) 95% accuracy (B) Mean (SD) Ratio (B/A) Mean (SD)
Overall mean (SD)a $611 (1462) $308 (561) 0.60 (0.48)
Range $0–10,000 $0–3000 0–1
Chance of getting breast cancer
Much higher $439 (453) $268 (340) 0.60 (0.45)
A little higher $428 (475) $300 (509) 0.58 (0.45)
The same or less $1245 (3090) $465 (909) 0.67 (0.37)
ANOVA test p value 0.37 0.70 0.87
Household monthly income
<$3000 $446 (519) $169 (223) 0.58 (0.49)
$3000–4999 $775 (1037) $495 (636) 0.57 (0.37)
>$5000 $698 (1774) $368 (651) 0.60 (0.43)
ANOVA test p value 0.92 0.59 0.99
Age
Up to 40 $371 (372) $292 (304) 0.72 (0.40)
41–49 $411 (629) $304 (403) 0.71 (0.40)
50–59 $962 (2142) $412 (768) 0.48 (0.43)
60 and older $220 (193) $58 (68) 0.62 (0.49)
ANOVA test p value 0.54 0.52 0.43
Previous biopsy
Yes $777 (2086) $329 (682) 0.47 (0.43)
With normal results $443 (440) $261 (402) 0.60 (0.42)
With benign results $1714 (3660) $589 (1096) 0.33 (0.47)
With positive cell changeb $183 (194) $116 (194) 0.46 (0.42)
No $476 (623) $293 (463) 0.69 (0.40)
t-test p value 0.52 0.83 0.09
Benign breast diseasec
Yes $1325 (2808) $523 (893) 0.45 (0.45)
No $379 (463) $238 (395) 0.65 (0.41)
t-test p value 0.27 0.31 0.17
Breast cancer
Yes $267 (208) $200 (265) 0.50 (0.50)
No $633 (1056) $315 (576) 0.60 (0.43)
t-test p value 0.16 0.73 0.69
Family history of breast cancer
Yes $436 (570) $236 (381) 0.53 (0.47)
No $778 (1975) $377 (693) 0.65 (0.39)
t-test p value 0.41 0.39 0.38
SD: Standard deviation.
a The difference in the willingness to pay to income ratio between 100 and 95% accuracy groups was significant (sign test, p <
0.0001).
b Including atypical hyperplasia, DCIS, LCIS, and malignancy.
c The willingness to pay ratio (B/A) was significantly different between those having and not having benign breast disease in the
non-parametric test, controlling for income (Kruskal–Wallis test, p = 0.027).
disease may be more worried about cancer. These
women may, judging from their experience, be more
willing to accept new technologies if these tests can
offer a confirmatory diagnosis and avoid unnecessary
surgical procedures. This explanation can also be ap-
plied to our finding that those who had prior benign
biopsy results were more willing to pay for new tests
than those who had prior abnormal biopsy results.
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Women with personal or family history of breast can-
cer are more likely to favor biopsy and less likely to
pay for new tests. This assumption is mirrored by our
finding that women with high levels of risk perception
were not as willing as those with lower levels of risk
perception to pay for new tests, even if the tests are
as good as biopsy in diagnosing breast cancer. Future
research should examine the associations between dis-
ease history and risk perception and willingness to pay
using a larger and diverse sample.
The interpretation of the results of this study is
limited by several factors. First, the generalizability
of our results is limited because we used a convenient
sample and no information on the number of decliners
and the reasons for refusals were available from the
referring clinics. However, since the diagnostic tests
were free of charge and scheduled on the same day,
refusal rates were expected to be minimal. Second, the
small sample size limited power to detect significant
relationships and the ability to determine the relative
importance of patient characteristics on willingness
to pay. Third, women’s understanding of each test
may not have been sufficiently accurate, since about
50% considered digital mammography less uncom-
fortable than routine mammography when in fact the
only difference is in imaging, and not in patient-related
procedures. However, women might actually expe-
rience less discomfort in digital mammography than
in previous mammography because they were more
nervous or had less skilled technicians during previous
mammography. On the other hand, a higher accept-
ability of digital mammography may simply reflect
women’s bias toward new technology. A more detailed
questionnaire is needed to understand the reasons for
rating discomfort and embarrassment. Fourth, the ratio
of willingness to pay and income were crude because
income was measured by category, not actual numer-
ical values. Finally, the high levels of satisfaction we
observed may have been affected by social desirability
biases and may over estimate true satisfaction.
Despite these limitations, this study one of the
first studies using a prospective cohort to assess the
satisfaction and acceptability of new breast cancer
diagnostic tests. We conclude that women would
find these tests acceptable, and would find the tests
preferable to biopsy if they were equally accurate or
nearly equally accurate at evaluating breast lesions
as biopsy. The development of novel breast can-
cer screening and diagnostic tests should focus on
women’s perceptions of comfort and preferences for
outcomes.
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